Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Systemic use of fluoroquinolone in children

  • Choi, Soo-Han (Department of Pediatrics, KEPCO Medical Foundation KEPCO Medical Center) ;
  • Kim, Eun Young (Department of Clinical Pharmacy, College of Pharmacy, Chung-Ang University) ;
  • Kim, Yae-Jean (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2012.12.18
  • Accepted : 2013.03.13
  • Published : 2013.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Fluoroquinolones are an important class of antibiotics that are widely used in adult patients because of their broad spectrum of activity, good tissue penetration, and oral bioavailability. However, fluoroquinolone use in children is limited because juvenile animals developed arthropathy in previous experiments on fluoroquinolone use. Indications for fluoroquinolone use in patients younger than 18 years, as stated by the U.S. Food and Drug Administration, include treatment of complicated urinary tract infections and postexposure treatment for inhalation anthrax. In Korea, the systemic use of fluoroquinolones has not been approved in children younger than 18 years. Although concerns remain regarding the adverse musculoskeletal effects of fluoroquinolones in children, their use in the pediatric population has increased in many circumstances. While pediatricians should be aware of the indications and adverse effects of fluoroquinolones, recent studies have shown that the risk for musculoskeletal complications in children did not significantly increase following fluoroquinolone treatment. In addition, fluoroquinolones may be particularly helpful in treating multidrug-resistant infections that have not responded to standard antibiotic therapy in immunocompromised patients. In the present article, we provide an updated review on the safety and current recommendations for using fluoroquinolones in children.

Keywords

References

  1. Karande SC, Kshirsagar NA. Adverse drug reaction monitoring of ciprofloxacin in pediatric practice. Indian Pediatr 1992;29:181-8.
  2. Lietman PS. Fluoroquinolone toxicities. An update. Drugs 1995;49 Suppl 2:159-63. https://doi.org/10.2165/00003495-199500492-00026
  3. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999;28:352-64. https://doi.org/10.1086/515104
  4. Andriole VT. The quinolones: past, present, and future. Clin Infect Dis 2005;41 Suppl 2:S113-9. https://doi.org/10.1086/428051
  5. Grady RW. Systemic quinolone antibiotics in children: a review of the use and safety. Expert Opin Drug Saf 2005;4:623-30. https://doi.org/10.1517/14740338.4.4.623
  6. Bonafede ME, Blumer JL. Role of newer broad-spectrum betalactam and fluoroquinolone antibiotics in children. Adv Pediatr Infect Dis 1996;12:71-108.
  7. White NJ, Dung NM, Vinh H, Bethell D, Hien TT. Fluoroquinolone antibiotics in children with multidrug resistant typhoid. Lancet 1996;348:547.
  8. Freifeld A, Pizzo P. Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients. Pediatr Infect Dis J 1997;16:140-5. https://doi.org/10.1097/00006454-199701000-00039
  9. Redmond AO. Risk-benefit experience of ciprofloxacin use in pediatric patients in the United Kingdom. Pediatr Infect Dis J 1997;16:147-9. https://doi.org/10.1097/00006454-199701000-00040
  10. Saez-Llorens X, McCoig C, Feris JM, Vargas SL, Klugman KP, Hussey GD, et al. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J 2002;21:14-22. https://doi.org/10.1097/00006454-200201000-00004
  11. Sideri G, Kafetzis DA, Vouloumanou EK, Papadatos JH, Papadimitriou M, Falagas ME. Ciprofloxacin in critically ill children. Anaesth Intensive Care 2011;39:635-9.
  12. Sung L, Manji A, Beyene J, Dupuis LL, Alexander S, Phillips R, et al. Fluoroquinolones in children with fever and neutropenia: a systematic review of prospective trials. Pediatr Infect Dis J 2012;31:431-5. https://doi.org/10.1097/INF.0b013e318245ab48
  13. Schaad UB. Fluoroquinolone antibiotics in infants and children. Infect Dis Clin North Am 2005;19:617-28. https://doi.org/10.1016/j.idc.2005.05.005
  14. Chien S, Wells TG, Blumer JL, Kearns GL, Bradley JS, Bocchini JA Jr, et al. Levofloxacin pharmacokinetics in children. J Clin Pharmacol 2005;45:153-60. https://doi.org/10.1177/0091270004271944
  15. Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics 2006;118:1287-92. https://doi.org/10.1542/peds.2006-1722
  16. Sabharwal V, Marchant CD. Fluoroquinolone use in children. Pediatr Infect Dis J 2006;25:257-8. https://doi.org/10.1097/01.inf.0000205799.35780.f3
  17. Velissariou IM. The use of fluoroquinolones in children: recent advances. Expert Rev Anti Infect Ther 2006;4:853-60. https://doi.org/10.1586/14787210.4.5.853
  18. Bradley JS, Jackson MA; Committee on Infectious Diseases; American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics 2011;128:e1034-45. https://doi.org/10.1542/peds.2011-1496
  19. Melhus A. Fluoroquinolones and tendon disorders. Expert Opin Drug Saf 2005;4:299-309. https://doi.org/10.1517/14740338.4.2.299
  20. Forsythe CT, Ernst ME. Do fluoroquinolones commonly cause arthropathy in children? CJEM 2007;9:459-62. https://doi.org/10.1017/S1481803500015517
  21. Sansone JM, Wilsman NJ, Leiferman EM, Conway J, Hutson P, Noonan KJ. The effect of fluoroquinolone antibiotics on growing cartilage in the lamb model. J Pediatr Orthop 2009;29:189-95. https://doi.org/10.1097/BPO.0b013e3181982c4f
  22. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002;324:1306-7. https://doi.org/10.1136/bmj.324.7349.1306
  23. Chalumeau M, Tonnelier S, D'Athis P, Treluyer JM, Gendrel D, Breart G, et al. Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France. Pediatrics 2003;111(6 Pt 1):e714-9. https://doi.org/10.1542/peds.111.6.e714
  24. U.S. Food and Drug Administration. Drug approval package: cipro (ciprofloxacin hydrochloride) tablets, cipro IV (ciprofloxacin) solution, cipro (ciprofloxacin) oral suspension [internet]. Silver Spring: U.S. Food and Drug Administration; [cited 2012 Nov 25]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/019537s49_19847s27_19857s31_20780s13TOC.cfm.
  25. Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child 2011;96:874-80. https://doi.org/10.1136/adc.2010.208843
  26. Kaguelidou F, Turner MA, Choonara I, Jacqz-Aigrain E. Ciprofloxacin use in neonates: a systematic review of the literature. Pediatr Infect Dis J 2011;30:e29-37. https://doi.org/10.1097/INF.0b013e3181fe353d
  27. Chaudhari S, Suryawanshi P, Ambardekar S, Chinchwadkar M, Kinare A. Safety profile of ciprofloxacin used for neonatal septicemia. Indian Pediatr 2004;41:1246-51.
  28. Dutta S, Chowdhary G, Kumar P, Mukhopadhay K, Narang A. Ciprofloxacin administration to very low birth weight babies has no effect on linear growth in infancy. J Trop Pediatr 2006;52:103-6.
  29. Noel GJ, Bradley JS, Kauffman RE, Duffy CM, Gerbino PG, Arguedas A, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 2007;26:879-91. https://doi.org/10.1097/INF.0b013e3180cbd382
  30. ClinicalTrials.gov. Moxifloxacin in pediatric subjects with complicated intra-abdominal infection (MOXIPEDIA) [Internet]. Bethesda: National Institutes of Health; [cited 2012 Nov 25]. Available from: http://clinicaltrials.gov/ct2/show/NCT01069900.
  31. ClinicalTrials.gov. Safety, tolerability and pharmacokinetics of single dose intravenous moxifloxacin in pediatric patients [Internet]. Bethesda: National Institutes of Health; [cited 2012 Nov 25]. Available from: http://clinicaltrials.gov/ct2/show/NCT01049022.
  32. Kim SC, Park YC, Kim BG, Nam DH. Outpatient antibiotic prescription by pediatric and ENT physicians in Ulsan city. Korean J Clin Pharm 2010;20:145-50.
  33. European Medicines Agency. 5-year report to the European Commision. General report on the experience acquired as a result of the application of the paediatric regulation [Internet]. London: European Medicines Agency; c2012 [cited 2012 Nov 25]. Available from: http://ec.europa.eu/health/files/paediatrics/2012-09_pediatric_report-annex1-2_en.pdf.
  34. European Medicines Agency. Ciprofloxacin Bayer - Article 30 referral - Annex I, II, II [Internet]. London: European Medicines Agency; c2012 [cited 2012 Nov 25]. Available from: http://www.ema.europa.ed/docs/en_GB/document_library/Referrals_document/Ciprofloxacin_Bayer_30/WC500008057.pdf.
  35. World Health Organization. Pocket book of hospital care for children [Internet]. Geneva: World Health Organization; c2013 [cited 2012 Nov 25]. Available from: http://www.who.int/maternal_child_adolescent/documents/9241546700/en/.
  36. World Health Organization. The selection and use of essential medicines. Report of the WHO expert committee, 2011 [Internet]. Geneva: World Health Organization; c2013 [cited 2012 Nov 25]. Available from: http://apps.who.int/iris/bitstream/10665/44771/1/WHO_TRS_965_eng.pdf.
  37. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011;53:e25-76. https://doi.org/10.1093/cid/cir531
  38. Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012;54:e72-e112. https://doi.org/10.1093/cid/cis370
  39. World Health Organization. Guidelines for the programtic management of drug-resistant tuberculosis - 2011 update [Internet]. Geneva: World Health Organization; c2013 [cited 2012 Nov 25]. Available from: http://apps.who.int/iris/bitstream/10665/44597/1/9789241501583_eng.pdf.
  40. Schaad UB. Will fluoroquinolones ever be recommended for common infections in children? Pediatr Infect Dis J 2007;26:865-7. https://doi.org/10.1097/INF.0b013e3180cc20e4

Cited by

  1. How multidrug resistance in typhoid fever affects treatment options vol.1323, pp.1, 2013, https://doi.org/10.1111/nyas.12490
  2. Aetiology of Acute Febrile Episodes in Children Attending Korogwe District Hospital in North-Eastern Tanzania vol.9, pp.8, 2014, https://doi.org/10.1371/journal.pone.0104197
  3. Primary Antimicrobial Susceptibility Changes in Children with Helicobacter pylori Infection over 13 Years in Northern Italy vol.2015, pp.None, 2013, https://doi.org/10.1155/2015/717349
  4. Bloodstream bacterial infection among outpatient children with acute febrile illness in north-eastern Tanzania vol.8, pp.None, 2013, https://doi.org/10.1186/s13104-015-1178-9
  5. The Antibiotic Resistance Pattern of Gram-Negative Bacteria in Children Younger Than 24 Months with a Urinary Tract Infection: A Retrospective Single-Center Study over 15 Consecutive Years vol.19, pp.2, 2013, https://doi.org/10.3339/chikd.2015.19.2.148
  6. Septic arthritis by Sphingobacterium multivorum in imunocompromised pediatric patient vol.34, pp.3, 2013, https://doi.org/10.1016/j.rpped.2015.12.001
  7. Septic arthritis by Sphingobacterium multivorum in immunocompromised pediatric patient vol.34, pp.3, 2013, https://doi.org/10.1016/j.rppede.2016.03.014
  8. Comparative Antibacterial Effects of the Whole and Diluted Human Breast Milk on some PCR Detected Diarrheagenic Escherichia coli (DEC) vol.11, pp.3, 2013, https://doi.org/10.22207/jpam.11.3.23
  9. Pediatric fluoroquinolone prescription in South Korea before and after a regulatory intervention: A nationwide study, 2007-2015 vol.12, pp.5, 2013, https://doi.org/10.1371/journal.pone.0176420
  10. Antibiotic resistance of Helicobacter pylori in Chinese children: A multicenter retrospective study over 7 years vol.22, pp.3, 2013, https://doi.org/10.1111/hel.12373
  11. Population dynamics of enteric Salmonella in response to antimicrobial use in beef feedlot cattle vol.7, pp.None, 2013, https://doi.org/10.1038/s41598-017-14751-9
  12. Pregnancy Outcomes Following Exposure to Quinolone Antibiotics - a Systematic-Review and Meta-Analysis vol.35, pp.5, 2013, https://doi.org/10.1007/s11095-018-2383-8
  13. In-Vitro Comparison of Antimicrobial Actions of Probiotics (Lactobacilli Species and Saccharomyces boulardii) with Standard Antibiotics for the Treatment of Diarrhea in Pediatric Population vol.9, pp.12, 2013, https://doi.org/10.4236/ijcm.2018.912069
  14. High Dose Ofloxacin-induced Bimodal Hallucinations in a Four Years Old Child vol.16, pp.2, 2018, https://doi.org/10.9758/cpn.2018.16.2.232
  15. Cytotoxicity of Ciprofloxacin and Steroids in Mouse Tympanic Membrane Fibroblasts vol.158, pp.3, 2013, https://doi.org/10.1177/0194599817751093
  16. Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children vol.11, pp.3, 2013, https://doi.org/10.1080/17512433.2018.1421067
  17. Effects of Common Ear Drops on Tympanic Membrane Healing in Rats vol.158, pp.5, 2013, https://doi.org/10.1177/0194599818757972
  18. Current Trends and Future Directions of Fluoroquinolones vol.26, pp.17, 2019, https://doi.org/10.2174/0929867325666180214122944
  19. Joint Modeling of Resistance to Six Antimicrobials in Urinary Escherichia coli Isolates in Quebec, Canada vol.63, pp.7, 2013, https://doi.org/10.1128/aac.02531-18
  20. Quinolones for sepsis. A protocol for a systematic review of randomised clinical trials with meta‐analysis and trial sequential analysis vol.63, pp.8, 2013, https://doi.org/10.1111/aas.13418
  21. Population Dynamics of Salmonella enterica within Beef Cattle Cohorts Followed from Single-Dose Metaphylactic Antibiotic Treatment until Slaughter vol.85, pp.23, 2013, https://doi.org/10.1128/aem.01386-19
  22. Efficient Synthesis and Antibacterial Profile of Bis(2-hydroxynaphthalene- 1,4-dione) vol.20, pp.2, 2013, https://doi.org/10.2174/1568026619666191210160342
  23. Decreased Susceptibility to Azithromycin in Clinical Shigella Isolates Associated with HIV and Sexually Transmitted Bacterial Diseases, Minnesota, USA, 2012–2015 vol.26, pp.4, 2013, https://doi.org/10.3201/eid2604.191031
  24. The incidence of collagen-associated adverse events in pediatric population with the use of fluoroquinolones: a nationwide cohort study in Taiwan vol.20, pp.1, 2020, https://doi.org/10.1186/s12887-020-1962-0
  25. Critical threat associated with carbapenem-resistant gram-negative bacteria: prioritizing water matrices in addressing total antibiotic resistance vol.70, pp.1, 2013, https://doi.org/10.1186/s13213-020-01579-4
  26. Variability in Antibiotic Treatment of Pediatric Surgical Site Infection After Spinal Fusion at A Single Institution vol.41, pp.6, 2021, https://doi.org/10.1097/bpo.0000000000001811
  27. An Update on the Management of Traumatic Pediatric Open Globe Repair: Prognostication and Complication Management vol.62, pp.1, 2013, https://doi.org/10.1097/iio.0000000000000399